These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 1232097)
1. The use of BCNU in chemotherapy of tumors of the central nervous system. Introzzi G; Paoletti P; Pezzotta S; Robustelli della Cuna G; Rodriguez y Baena R J Neurosurg Sci; 1975; 19(4):223-5. PubMed ID: 1232097 [No Abstract] [Full Text] [Related]
2. Long-term survival of patients treated with BCNU for brain tumors. Calogero J; Crafts DC; Wilson CB; Boldrey EB; Rosenberg A; Enot KJ J Neurosurg; 1975 Aug; 43(2):191-6. PubMed ID: 1185250 [TBL] [Abstract][Full Text] [Related]
7. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548 [TBL] [Abstract][Full Text] [Related]
8. A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. Levin VA; Wilson CB; Davis R; Wara WM; Pischer TL; Irwin L J Neurosurg; 1979 Oct; 51(4):526-32. PubMed ID: 225456 [No Abstract] [Full Text] [Related]
9. Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation. Eagan RT; Dinapoli RP; Hermann RC; Groover RV; Layton DD; Scott M Cancer Treat Rep; 1982 Aug; 66(8):1647-9. PubMed ID: 7105055 [No Abstract] [Full Text] [Related]
10. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. Buckner JC; Brown LD; Kugler JW; Cascino TL; Krook JE; Mailliard JA; Kardinal CG; Tschetter LK; O'Fallon JR; Scheithauer BW J Neurosurg; 1995 Mar; 82(3):430-5. PubMed ID: 7861221 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of supratentorial glioma with intracarotid cisplatin and intravenous carmustine]. Rebollo J; Martín-Algarra S; Bilbao I; Zubieta JL; Calvo FA; de Castro P; Pastor MA; Viteri C; Martínez Lage JM Neurologia; 1990; 5(7):228-32. PubMed ID: 1963067 [TBL] [Abstract][Full Text] [Related]
12. Sensitivity of human malignant intracranial tumors against MCNU in vitro in comparison to ACNU and BCNU. Tonn JC; Schönmayr R; Kraemer HP J Neurooncol; 1990 Feb; 8(1):41-5. PubMed ID: 2319289 [TBL] [Abstract][Full Text] [Related]
16. [Value of chemotherapy associated with conventional treatment of malignant gliomas of the brain. Study of 95 cases with histological verification and follow-up of 1 to 6 years 9 months]. Paillas JE; Prince MA; Hassoun J; Pellet W; Peragut JC Rev Neurol (Paris); 1979 Mar; 135(3):251-62. PubMed ID: 227020 [No Abstract] [Full Text] [Related]
17. Effect of intra-arterial cisplatin and 1,3-bis(2chloroethyl)-1-nitrosourea (BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: proposal of a new method of intra-arterial dosage calculation. Bobo H; Kapp JP; Vance R J Neurooncol; 1992 Jul; 13(3):291-9. PubMed ID: 1517805 [TBL] [Abstract][Full Text] [Related]
18. The contemporary role of chemotherapy in the treatment of malignant brain tumor. Walker MD Clin Neurosurg; 1978; 25():388-96. PubMed ID: 710004 [No Abstract] [Full Text] [Related]